Clincosm LogoSign in Get a demo

HCC and FTC: Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma

Sponsor
The Catholic University of Korea (Other)
Overall Status
Completed
CT.gov ID
NCT05968196
Collaborator
(none)
221
Enrollment
278.9
Actual Duration (Months)

Study Details

Study Description

Brief Summary

The goal of this retrospective study is to evaluate in patients with HCC and FTC who underwent lobectomy. The main questions it aims to answer are:

  • The necessity of completion thyroidectomy based on the clinicopathological characteristics

  • Prognosis Participants underwent thyroid lobectomy Researchers compared HCC and FTC groups to see the prognosis after lobectomy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Background The prognosis of Hürthle cell carcinoma (HCC) and follicular thyroid carcinoma (FTC) is poorly understood. These types of cancers are usually confirmed after diagnostic lobectomy. We aimed to evaluate the clinicopathological characteristics and prognoses of patients with HCC and FTC who did not undergo completion thyroidectomy.

    Materials and Methods We screened 221 patients diagnosed with FTC or HCC after thyroid lobectomy at Yonsei Severance Hospital between January 2000 and December 2020. After excluding patients who underwent complete thyroidectomy, 184 patients with FTC and 37 patients with HCC were included.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    221 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Clinicopathological Characteristics of Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma Without Completion Thyroidectomy
    Actual Study Start Date :
    Jan 1, 2000
    Actual Primary Completion Date :
    Dec 31, 2020
    Actual Study Completion Date :
    Mar 31, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    FTC

    Follicular thyroid carcinoma
    HCC

    Hurthle cell carcinoma

    Outcome Measures

    Primary Outcome Measures

    1. Disease-free survival (DFS) [From January 2000 to March 2023]

      a comparison of disease-free survival (DFS) between FTC and HCC groups

    Secondary Outcome Measures

    1. TNM stage [From January 2000 to March 2023]

      a comparison of TNM stage between FTC and HCC groups

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Follicular thyroid carcinoma

    • Hurthle cell carcinoma

    • Lobectomy

    Exclusion Criteria:

    • Completion thyroidectomy

    • Total thyroidectomy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • The Catholic University of Korea

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kwangsoon Kim, Assistant Professor, The Catholic University of Korea
    ClinicalTrials.gov Identifier:
    NCT05968196
    Other Study ID Numbers:
    • noar99
    First Posted:
    Aug 1, 2023
    Last Update Posted:
    Aug 1, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Carcinoma
    Thyroid Neoplasms
    Adenocarcinoma, Follicular
    Adenocarcinoma

    Study Results

    No Results Posted as of Aug 1, 2023